The interference of immunoglobulins in the radioimmunoassay (RIA) of human ß-endorphin was investigated. Human IgM showed no cross-reactivity. Human IgA showed a weak cross-reaction, but the dilution curve of IgA did not show parallelism with the standard curve of ß-endorphin, thus indicating its antigenic difference. The dilution curves of human IgG showed 0.18% displacement with respect to the human ß-endorphin standard curve, with good parallelism. Moreover, five patients with multiple myeloma of the IgG type showed falsely elevated ß-endorphin levels. We investigated the possibility that certain IgGs may be responsible for the displacement of [ 125 I] ß-endorphin in the ß-endorphin kit. The apparent ß-endorphin level of plasma from multiple myeloma patients was markedly decreased after affinity chromatography of the serum on protein A-Sepharose.
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Normal subjects and patients
Normal ß-endorphin values were determined in 82 normal healthy volunteers (43 males; 49 females; aged 18 -65) whose blood was collected between 0800 and 0900. The blood samples (5 -10 ml) were collected in plastic tubes by venipuncture containing 2 g/1 EDTA; centrifuged within 15 min, the plasma separated and immediately frozen at -20 °C. Six of the volunteers were given metyrapone, 2.0 g orally at 9 a. m., with blood samples drawn immediately beforehand and after 6 h and 8 h. From the volunteer group blood samples for ß-endorphin, corticotropin and cortisol were obtained from 6 subjects at 11 p.m., followed by the administration of 1.0 mg of dexamethasone orally. At 6 a. m. and 8 a. m. further blood samples were obtained. Six more normal subjects underwent an insulin tolerance test (monocomponent insulin 0.1 U/kg). During this test blood samples were taken via an intravenous cannula at -30, -15, 0, 15, 30, 60, 90, and 120 min and assayed for glucose, corticotropin, ß-endorphin, cortisol and insulin.
Five patients with pituitary corticotropin-dependent Cushing's disease who had been bilaterally adrenalectomized and five patients with Addison's disease receiving corticosteroid replacement therapy were studied. Replacement therapy was omitted on the morning of the study; venous blood samples were taken at 0900 h and thereafter at 30 min intervals for 3 h, and were assayed for corticotropin, ß-endorphin and cortisol. Five patients with multiple myeloma of the IgG type (3 Lambda, 2 Kappa) had plasma taken for ß-endorphin assay. These samples were assayed with and without affinity chromatography on staphylococcal protein A-Sepharose.
Materials and Methods
Concentrations of immunoreactive ß-endorphin were determined by means of a commercial radioimmunoassay kit developed by the New England Nuclear Company, Boston, MA, USA, with antiserum from rabbits prepared against synthetic human ß-endorphin (synthesized by the Peptide Division of the Beckman Company, FRG). Synthetic ß-endorphin was labelled with Na 125 I using chloramine T. The specific activity of [ 125 I]ß-endorphin ranged from 56.1 to 83.6 TBq/mmol. The assay was performed according to the following protocol. Briefly, 0.1 ml specimen was used. Synthetic human ß-endorphin served as a standard. The antiserum to ß-endorphin was used at a final dilution of 1:8000. Separation of the bound, from free antigen, was achieved by adsorption onto activated charcoal. The specificity of the ß-endorphin antiserum was 50% for ß-lipotropic hormone (ß-lipotropin), less than 0.01% for oc-endorphin and oc-melanocyte stimulating hormone ( -melanotropin), and less than 0.004% for leu-enkephalin and met-enkephalin. The minimal detectable dose was 5.0 pmol/1. The intra-and interassay variation were 5.6% and 12% respectively. To ensure the accuracy of our RIA in the determination of human plasma ß-endorphin levels, we performed dexamethasone supression tests, insulin hypoglycaemia tests and metyrapone tests on normal healthy subjects; the results were in agreement with previously reported values for ß-endorphin in these tests. In our laboratory the ß-endorphin levels ranged from 5 -30 pmol/1. 
Results
Plasma ß-endorphin concentrations Table 1 shows the circulating plasma ß-endorphin levels in 82 healthy normal subjects, 5 bilaterally adrenalectomized patients with Cushing's disease and 5 patients with Addison's disease. During the dexamethasone suppression tests the plasma ß-endorphin levels fell in each subject and rose during the insulininduced hypoglycaemia and metyrapone tests. All the patients with Cushing's disease and Addison's disease had elevated plasma ß-endorphin and corticotropin concentrations. Table 2 shows the ß-endorphin levels in patients with multiple myeloma of the IgG type. All the patients showed high plasma ß-endorphin levels but within the normal range, but then showed a marked decline after affinity chromatography on staphylococcal protein ASepharose, which suggests IgG interference.
The effect of human IgG, A, M, on the ß-endorphin radioimmunoassay
The dilution curve of human IgA and IgM did not show parallelism with the human ß-endorphin standard curve, suggesting the IgA and IgM do not possess sequence homologies to ß-endorphin. In contrast, commercial human IgG causes a significant displacement of labelled ß-endorphin, with good parallelism (fig. 1); i. e. the dilution curves of IgG from Miles Labs, Cappel Labs and Kabi company showed 0.20%, 0.18% and 0.16% cross-reactivity, respectively, with the standard curve for ß-endorphin, thus indicating immunological identity. After affinity chromatography of the serum on staphylococcal protein A-Sepharose (13), no immunological cross-reactivity was observed.
The effect of IgG on human pituitary hormone radioimmunoassays
No immunological effect of IgG was found in the radioimmunoassays for lutropin, follitropin, thyrotropin, prolactin or somatotropin, indicating that there is no immunological similarity between the amino acid sequences of these hormones and that of IgG.
Discussion
The circulating human ß-endorphin levels were checked by radioimmunoassay and were found to be 5 -30 pmol/1. Moreover, the ß-endorphin response in the dexamethasone suppression test, insulin hypoglycaemia test and metyrapone test showed results corresponding to those previously reported (14 -17) .
In 1980, Julliard et al. (12) discovered structual homologies between ß-endorphin and IgG using a computer program. They synthesized a fragment of human IgG heavy chain 363 to 379 (VSLTCLVKGFYPSDIAV) by solid-phase techniques and reported that this fragment showed 0.18 percent displacement of the human ß-endorphin tracer, with good parallelism. Our present study concurs with Julliard s finding (12) .
This result suggested that spuriously high ß-endorphin levels may be obtained in patients with high -globulinaemia. Therefore a preliminary examination of three patients with IgG myeloma was carried out. Their lyophilized IgG, diluted with saline to a concentration of 177, 185, 162 g/1, indeed showed high ß-endorphin values, i.e. 20.2, 25.5, 21.2 pmol/1, respectively, but showed negligible ß-endorphin levels after the removal of IgG proteins by affinity chromatography on protein A-Sepharose. It is therefore concluded that the pseudo-ß-endorphin activity of human plasma proteins is essentially due to the effect of IgG per se. To cross check the accuracy of these results we pre-added ß-endorphin to the IgG solution from the same patients and carried out affinity chromatography. The subsequent recovery of ß-endorphin was 95.6 ± 2.3% (Mean ± SE), thus demonstrating that there were no changes in concentration of ß-endorphin in the IgG solution. This study clearly excludes the possibility that the ß-endorphin is noncovalently linked to IgG. Moreover, in order to confirm our hypothesis we performed further experiments using the plasma from five other patients suffering from IgG myeloma. We studied the ß-endorphin levels before and after staphylococcal affinity chromatography on protein A-Sepharose. As shown in table 2 the plasma ß-endorphin levels were elevated before and markedly decreased after. These results clearly indicate IgG interference in the human ß-endorphin radioimmunoassay.
Julliard et al. (12) reported that their studies had led to the unexpected recognition of several homologies in the amino acid sequences of two physiologically unrelated substances, such as pituitary hormone (ß-endorphin and corticotropin) and the constant chain of an IgG. We therefore conducted a further study on the effect of IgG proteins on the radioimmun oassays of several pituitary hormones, in order to investigate the possibility of other unexpected relationships. In our studies of peptide hormones, no immunological similarities to IgG were found. However, the observation made by Julliard et al. (12) does seem important, and there may be other cases of substances arising from the same origin, which previously have been thought to be unrelated. Very recently a study by Campino et al. (18) described that immunoreactive human growth hormone, in a patient with acromegaly, is in fact IgG. Additional studies are expected.
Through our studies, it has become clear that to avoid IgG interference a specific monoclonal antibody which recognises the epitope of ß-endorphin is preferable to using polyclonal antibodies raised in animals. The use of such a specific monoclonal antibody would avoid the spuriously high results for ß-endorphin in patients with high IgG levels. Recently Voellmy et al. (19) reported a two-site immunoradiometric assay for human ß-endorphin using a polyclonal rabbit anti-ß-endorphin antibody and an 125 Ilabeled monoclonal mouse antibody 3-E7, which binds to the N-terminal region of ß-endorphin. If no IgG effect is demonstrated with this newly developed monoclonal antibody method, we can anticipate greater accuracy and reliability in the determination of ß-endorphin concentrations.
